Primary Lateral Sclerosis Clinical Trials

Find Primary Lateral Sclerosis Clinical Trials Near You

Modeling of Amyotrophic Lateral Sclerosis Using Patient Fibroblasts to Study Different Form of the Disease.

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying pathogenic mutations responsible for ALS, and control subjects. In this study, a skin biopsy and blood sampling will be performed at the initial visit (M0), then at M12 (+/- 2 months) for patients, and at M36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. The aim of this research is to model ALS pathology using fibroblasts derived from the patients' skin biopsies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• adults, both sexes

• with written consent to participate in the study

• affiliated to a social security scheme

⁃ ALS patients :

• patients with ALS according to the revised El Escorial criteria :

• with a hereditary form of ALS, defined by the presence of a family history of ALS or by the demonstration of a pathogenic mutation in the patient or

• with a juvenile form of the disease, defined by onset of symptoms at less than 30 years of age or

• with a sporadic form of ALS

⁃ Asymptomatic mutation carriers :

⁃ \- Asymptomatic individuals who carry a mutation causing ALS but have not developed symptoms.

⁃ Healthy subjects:

• control individuals, taking into account male/female and close age matching

Locations
Other Locations
France
CIC Neurosciences
RECRUITING
Paris
Contact Information
Primary
Maria del Mar Amador, MD
mariadelmar.amador@aphp.fr
33142162472
Time Frame
Start Date: 2025-08-28
Estimated Completion Date: 2034-09
Participants
Target number of participants: 110
Treatments
Experimental: participants (SLA, healthy controls and asymptomatics)
Patients fulfilling the El Escorial criteria definite ALS or asymptomatics or Healthy controls
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov